Navigation Links
Syngenta and Devgen enter insect control research partnership

BASEL, Switzerland, May 14, 2012

  • License to access novel insect control technology
  • New range of biological solutions for hard-to-control insects
  • Development of new commercial offers for growers

Syngenta and Devgen today announced a six-year global license and research agreement. The partnership will enable Syngenta to add RNA interference (RNAi) technology to its crop protection pipeline. As of April 2013, the two companies will jointly develop new biological insect control solutions based on RNAi technology.

Under the agreement, Syngenta will develop and commercialize sprayable RNAi-based crop protection products originating from Devgen. Devgen will bolster its research activities through funding and royalties from Syngenta, consisting of an upfront technology access payment of EUR 22m and EUR 4.8m per year to fund research over the course of the agreement. Devgen is eligible to receive royalties from Syngenta on sales of developed products.

"We are pleased to enter this research partnership with Devgen given their leading position in RNAi research and proven expertise in RNAi-based insect control," said Sandro Aruffo, Global Head of Research and Development. "This novel technology further expands our growing range of biological insect control solutions."

"We are pleased to have Syngenta, a leading crop protection and seed company, as partner in the RNAi field. This relationship will enable Devgen to further and fully exploit the potential of this exciting technology for spray applications," says Thierry Bogaert, CEO of Devgen.

RNAi is a naturally occurring process in all organisms. In agriculture, RNAi is developed to target and control a specific pest, thereby protecting high-value crops with no harm to beneficial insects.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.  


Syngenta International AG

Media Office

CH-4002 Basel


Tel: +41 61 323 23 23

Fax: +41 61 323 24 24

Media contact:

Daniel Braxton

Switzerland +41 61 323 2323

Analyst/Investor contact:

Jennifer Gough

Switzerland +41 61 323 5059

USA +1 202 737 6521


SOURCE Syngenta
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
2. Syngenta and Metabolon Inc. in Collaborative Research Agreement for Biochemical Profiling Technology
3. Syngenta Enters Into Research Collaboration With Anhui Academy, China
4. Syngenta Board Proposes Stefan Borgas to Become New Director
5. Syngenta holds Annual General Meeting
6. Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields
7. Syngenta Issues EUR 500 Million Eurobond
8. Syngenta and Evogene to Collaborate on Soybean Nematode Resistance
9. Syngenta Licenses Chromatin Gene Stacking Technology for Sugar Cane
10. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
11. Syngenta joins Sustainability Consortium as Founding Member
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... GA (PRWEB) , ... November 30, 2015 , ... ... a new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 ... will embark on a worldwide tour including several North American tour dates. The ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):